protozoan vaccines

Summary

Summary: Suspensions of attenuated or killed protozoa administered for the prevention or treatment of infectious protozoan disease.

Top Publications

  1. ncbi Vaccine development against Trypanosoma cruzi and Chagas disease
    Juan C Vazquez-Chagoyan
    Centro de Investigación y Estudios Avanzados en Salud Animal, Facultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma de Estado de México, Toluca, Mexico
    Adv Parasitol 75:121-46. 2011
  2. ncbi Second-generation vaccines against leishmaniasis
    Rhea N Coler
    The Infectious Disease Research Institute, 1124 Columbia Street, Suite 600, Seattle, WA 98104, USA
    Trends Parasitol 21:244-9. 2005
  3. ncbi Enhancement of protective immune responses induced by Toxoplasma gondii dense granule antigen 7 (GRA7) against toxoplasmosis in mice using a prime-boost vaccination strategy
    Juan Min
    Department of Parasitology, Shandong University School of Medicine, Jinan, Shandong 250012, PR China
    Vaccine 30:5631-6. 2012
  4. ncbi Toxoplasma gondii: bioinformatics analysis, cloning and expression of a novel protein TgIMP1
    Yang Bai
    Department of Parasitology, Shandong University School of Medicine, Jinan, Shandong Province 250012, PR China
    Exp Parasitol 132:458-64. 2012
  5. ncbi Toxoplasma gondii immune mapped protein-1 (TgIMP1) is a novel vaccine candidate against toxoplasmosis
    Xia Cui
    Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China
    Vaccine 30:2282-7. 2012
  6. ncbi Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells
    Erik Jongert
    Laboratory for Toxoplasmosis, Pasteur Institute of Brussels, Brussels, Belgium
    Vaccine 28:2556-64. 2010
  7. ncbi Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase
    Alexandre V Machado
    Departamento de Bioquimica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte 31270 910, Brazil
    Hum Gene Ther 17:898-908. 2006
  8. ncbi Development of a vaccine for toxoplasmosis: current status
    Girish M Bhopale
    Parasitology and Immunodiagnostic Laboratory, Research and Development Division, Hindustan Antibiotics Ltd, Pimpri, Pune 411018, India
    Microbes Infect 5:457-62. 2003
  9. ncbi Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis
    Sima Rafati
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
    Vaccine 24:2169-75. 2006
  10. pmc DNA vaccination with a gene encoding Toxoplasma gondii GRA6 induces partial protection against toxoplasmosis in BALB/c mice
    Xi Meng Sun
    National Animal Protozoa Laboratory and College of Veterinary Medicine, China Agricultural University, Beijing 100193, China
    Parasit Vectors 4:213. 2011

Research Grants

  1. MOLECULAR TOOLS TO DEVELOP HAMSTER MODELS OF DISEASE
    Peter Melby; Fiscal Year: 2003
  2. VACCINATION OF DOGS TO REDUCE TRANSMISSION OF LEISHMANIA
    Peter Melby; Fiscal Year: 2003
  3. NOS2 and arginase in visceral leishmaniasis
    Peter Melby; Fiscal Year: 2009
  4. EFFECT OF MORPHINE ON IMMUNE RESISTANCE TO T GONDII
    Lawrence Johnson; Fiscal Year: 2002
  5. Regulation of innate immunity to infection
    Lawrence Johnson; Fiscal Year: 2005
  6. Vaccine Induced Mucosal Protection Against TB Infection
    DANIEL HOFT; Fiscal Year: 2005
  7. B CELL DEPENDENT IMMUNITY TO TOXOPLASMA GONDII
    Lawrence Johnson; Fiscal Year: 2004
  8. Vaccine Discovery for Chagas Disease
    Rick Tarleton; Fiscal Year: 2008
  9. ADHERENCE BLOCKING VACCINE FOR AMEBIASIS
    William Petri; Fiscal Year: 2003
  10. Drug Discovery Consortium for Chagas Disease
    Rick L Tarleton; Fiscal Year: 2010

Detail Information

Publications240 found, 100 shown here

  1. ncbi Vaccine development against Trypanosoma cruzi and Chagas disease
    Juan C Vazquez-Chagoyan
    Centro de Investigación y Estudios Avanzados en Salud Animal, Facultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma de Estado de México, Toluca, Mexico
    Adv Parasitol 75:121-46. 2011
    ..cruzi in experimental animals. This review summarizes the research efforts in vaccine development against Chagas disease during the past decade...
  2. ncbi Second-generation vaccines against leishmaniasis
    Rhea N Coler
    The Infectious Disease Research Institute, 1124 Columbia Street, Suite 600, Seattle, WA 98104, USA
    Trends Parasitol 21:244-9. 2005
    ..In addition, several antigens have been identified and characterized that might be potential vaccine candidates. In this article, we focus on advances made with second-generation vaccines against leishmaniasis...
  3. ncbi Enhancement of protective immune responses induced by Toxoplasma gondii dense granule antigen 7 (GRA7) against toxoplasmosis in mice using a prime-boost vaccination strategy
    Juan Min
    Department of Parasitology, Shandong University School of Medicine, Jinan, Shandong 250012, PR China
    Vaccine 30:5631-6. 2012
    ..Therefore, the DNA prime-protein boost vaccination based on GRA7 might be a promising regimen for further development of an effective vaccine against T. gondii...
  4. ncbi Toxoplasma gondii: bioinformatics analysis, cloning and expression of a novel protein TgIMP1
    Yang Bai
    Department of Parasitology, Shandong University School of Medicine, Jinan, Shandong Province 250012, PR China
    Exp Parasitol 132:458-64. 2012
    ..1-TgIMP1 was transfected into cells of HFF, and then identified by RT-PCR. The results showed that the eukaryotic expression plasmid pBudCE4.1-TgIMP1 was constructed and was transfected to the HFF cells successfully...
  5. ncbi Toxoplasma gondii immune mapped protein-1 (TgIMP1) is a novel vaccine candidate against toxoplasmosis
    Xia Cui
    Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China
    Vaccine 30:2282-7. 2012
    ..8 ± 6 days) prolonged survival time compared with control mice, which died within 7 days of challenge infection. These results suggest that IMP1 is a promising vaccine candidate against toxoplasmosis...
  6. ncbi Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells
    Erik Jongert
    Laboratory for Toxoplasmosis, Pasteur Institute of Brussels, Brussels, Belgium
    Vaccine 28:2556-64. 2010
    ..The results obtained in this work suggest that distinct in vivo cytolytic effector mechanisms are at work in DNA vaccinated and latently infected mice, but both converge to protect against acute toxoplasmosis...
  7. ncbi Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase
    Alexandre V Machado
    Departamento de Bioquimica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte 31270 910, Brazil
    Hum Gene Ther 17:898-908. 2006
    ..Taking together, these results show that recombinant adenoviruses expressing TS and ASP-2 antigens of T. cruzi are interesting candidates for the development of a vaccine against Chagas' disease...
  8. ncbi Development of a vaccine for toxoplasmosis: current status
    Girish M Bhopale
    Parasitology and Immunodiagnostic Laboratory, Research and Development Division, Hindustan Antibiotics Ltd, Pimpri, Pune 411018, India
    Microbes Infect 5:457-62. 2003
    ..Recent progress in knowledge of the protective immune response generated by Toxoplasma gondii and the current status of development of a vaccine for toxoplasmosis are highlighted...
  9. ncbi Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis
    Sima Rafati
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
    Vaccine 24:2169-75. 2006
    ....
  10. pmc DNA vaccination with a gene encoding Toxoplasma gondii GRA6 induces partial protection against toxoplasmosis in BALB/c mice
    Xi Meng Sun
    National Animal Protozoa Laboratory and College of Veterinary Medicine, China Agricultural University, Beijing 100193, China
    Parasit Vectors 4:213. 2011
    ..gondii infected BALB/c mice with an H-2Ld gene. The CD8+ T cell response of H-2Ld mice infected by the T. gondii strain seemed to target entirely to a single GRA6 peptide HF10-H-2Ld complex...
  11. ncbi Vaccines against Toxoplasma gondii: challenges and opportunities
    Erik Jongert
    Laboratory for Toxoplasmosis, Pasteur Institute of Brussels, Scientific Institute for Public Health, Brussels, Belgium
    Mem Inst Oswaldo Cruz 104:252-66. 2009
    ..Endpoints like maternal-foetal transmission and prevention of eye disease are important in addition to the traditional endpoint of survival or reduction in numbers of brain cysts after challenge...
  12. pmc Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination
    Barbara Papadopoulou
    Centre de Recherche en Infectiologie du Centre de Recherche du CHUL and Division de Microbiologie, Faculte de Medecine, Universite Laval, Quebec, Canada
    Infect Immun 70:62-8. 2002
    ..Overall, these results show that by genetically manipulating the pterin transport in L. donovani, it is possible to generate an attenuated organism that could be part of a vaccination strategy...
  13. pmc Protective efficacy of a Toxoplasma gondii rhoptry protein 13 plasmid DNA vaccine in mice
    Pei Yuan Wang
    State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province, People s Republic of China
    Clin Vaccine Immunol 19:1916-20. 2012
    ..gondii cyst infection and that it is a potential vaccine candidate against toxoplasmosis, which provided the foundation for further development of effective vaccines against T. gondii...
  14. ncbi Chasing the golden egg: vaccination against poultry coccidiosis
    P A Sharman
    Institute for the Biotechnology of Infectious Diseases, University of Technology, Sydney, NSW, Australia
    Parasite Immunol 32:590-8. 2010
    ....
  15. ncbi Toxoplasma gondii: humoral and cellular immune response of BALB/c mice immunized via intranasal route with rTgROP2
    Michelle Igarashi
    Laboratório de Protozoologia, Departamento de Medicina Veterinaria Preventiva, Universidade de Londrina, Londrina PR, Brazil
    Rev Bras Parasitol Vet 19:210-6. 2010
    ..mL(-1) of rTgROP2. These results indicate that intranasal immunization with recombinant protein ROP2 plus Quil-A can elicit both cellular and humoral immune responses in BALB/c mice...
  16. pmc Vaccines to combat the neglected tropical diseases
    Jeffrey M Bethony
    Microbiology, Immunology, and Tropical Medicine, George Washington University Medical Center, Washington, DC 20037, USA
    Immunol Rev 239:237-70. 2011
    ..Also highlighted are the contributions being made by non-profit product development partnerships that are working to overcome some of the economic challenges in vaccine manufacture, clinical testing, and global access...
  17. ncbi Toxoplasma gondii microneme protein 6 (MIC6) is a potential vaccine candidate against toxoplasmosis in mice
    Gao Hui Peng
    Department of Parasitology, College of Veterinary Medicine, South China Agricultural University, 483 Wushan Street, Tianhe District, Guangzhou, Guangdong Province 510642, People s Republic of China
    Vaccine 27:6570-4. 2009
    ..Our data demonstrate, for the first time, that MIC6 triggered a strong humoral and cellular response against T. gondii, and that the antigen is a potential vaccine candidate against toxoplasmosis, worth further development...
  18. ncbi Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines
    Hamid Daneshvar
    Division of Infection and Immunity, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, United Kingdom
    J Infect Dis 187:1662-8. 2003
    ..mexicana retained its properties in gentamicin-free medium over 40 subcultures. The attenuated lines of L. mexicana and L. major both induced significant protection in mice against challenge with wild-type parasites...
  19. ncbi Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection
    Vanesa R Sánchez
    Laboratorio de Inmunologia, Centro de Salud y Medio Ambiente, Escuela de Ciencia y Tecnologia, Universidad Nacional de San Martin, Av Gral Paz 5445, San Martin, 1650 Buenos Aires, Argentina
    Exp Parasitol 128:448-53. 2011
    ..Taken together, these results indicate that CpG-ODN is an important candidate adjuvant for use in potential multicomponent anti-T. gondii vaccines for animals and humans...
  20. ncbi Chagas disease (American trypanosomiasis) in Mexico: an update
    Alejandro Carabarin-Lima
    Department of Molecular Biology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City 14080, Mexico
    Acta Trop 127:126-35. 2013
    ..We hope that this review sensitizes the relevant authorities and that the appropriate measures to reduce the risk of infection by T. cruzi are undertaken to provide the Mexican people a better quality of life...
  21. ncbi Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum
    J Poot
    Intervet International B V, Parasitology R and D, Wim de Korverstraat 35, 5831AN Boxmeer, The Netherlands
    Vaccine 24:2460-8. 2006
    ..More plausible explanations are the dose and timing of the IL-12 application and the potentially different effects IL-12 induces as an adjuvant in either the murine or the canine leishmaniosis model...
  22. ncbi Current status of vaccination against African trypanosomiasis
    Stefan Magez
    Unit of Cellular and Molecular Immunology, Vrije Universiteit Brussel VUB, Pleinlaan 2, B 1050 Brussels, Belgium
    Parasitology 137:2017-27. 2010
    ..This paper reviews past and current attempts to design both anti-trypanosome vaccines, as well as vaccines directed towards the inhibition of infection-associated pathology...
  23. ncbi Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity
    Alexandre V Machado
    Departamento de Bioquimica e Imunologia, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270 910, MG, Brazil
    Vaccine 28:3247-56. 2010
    ..gondii, they displayed up to 85% of reduction in parasite burden. These results demonstrate the potential use of recombinant influenza vectors harboring the dicistronic segments in the development of vaccines against infectious diseases...
  24. ncbi The protective effect of a Toxoplasma gondii SAG1 plasmid DNA vaccine in mice is enhanced with IL-18
    Quan Liu
    Institute of Military Veterinary, Academy of Military Medical Sciences, Changchun 130062, Jilin Province, China
    Res Vet Sci 89:93-7. 2010
    ..Therefore, codelivery of the IL-18-secreting plasmid potentiates the induction and maintenance of the type 1 helper T-cell immune response and may be a potent strategy for enhancing the protective efficacy of vaccines against T. gondii...
  25. ncbi Immunization with MIC1 and MIC4 induces protective immunity against Toxoplasma gondii
    Elaine V Lourenço
    Laboratório de Imunoquímica e Glicobiologia, Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Av dos Bandeirantes, 3900, Ribeirao Preto SP, CEP 14 049 900, Brazil
    Microbes Infect 8:1244-51. 2006
    ..Our data demonstrate that MIC1 and MIC4 triggered a protective response against toxoplasmosis, and that these antigens are targets for the further development of a vaccine...
  26. pmc Distinct kinetics of effector CD8+ cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice
    Fanny Tzelepis
    CINTERGEN, UNIFESP Escola Paulista de Medicina, Rua Mirassol, 207, Sao Paulo SP, Brazil, 04044 010
    Infect Immun 74:2477-81. 2006
    ..In contrast, in vaccinated mice, the swift CD8+-T-cell response helps host survival after challenge...
  27. ncbi Molecular and immunological characterisation of Theileria parva stocks which are components of the 'Muguga cocktail' used for vaccination against East Coast fever in cattle
    R Bishop
    International Livestock Research Institute ILRI, P O Box 30709, Nairobi, Kenya
    Vet Parasitol 94:227-37. 2001
    ..parva Muguga and Serengeti-transformed components in the immunising cocktail. The study demonstrates the value of molecular characterisation data for monitoring of live vaccines...
  28. ncbi Protective effect against toxoplasmosis in mice induced by DNA immunization with gene encoding Toxoplasma gondii ROP18
    Zi Guo Yuan
    State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, CAAS, Lanzhou, Gansu Province 730046, PR China
    Vaccine 29:6614-9. 2011
    ..05). Our results show for the first time, that a ROP18 vaccine construct can enhance the T. gondii-specific CTL. Th1 responses and increased survival suggested that ROP18 is a promising vaccine candidate against infection with T. gondii...
  29. ncbi Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN)
    G P Borja-Cabrera
    Instituto de Microbiologia, Prof Paulo de Góes, Universidade Federal do Rio de Janeiro UFRJ, CCS, Cidade Universitaria, Ilha do Fundao, Caixa Postal 68040, CEP 21941 590, Brazil
    Vaccine 20:3277-84. 2002
    ..Higher seropositivities and intradermal reactions with no Leishmanial DNA were detected in vaccinees. The FML-QuilA vaccine induced a significant, long lasting and strong protective effect against canine kala-azar in the field...
  30. ncbi Canine leishmaniasis: epidemiological risk and the experimental model
    Javier Moreno
    WHO Collaborating Centre for Leishmaniasis, Servicio de Parasitologi a, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Ctra Majadahonda Pozuelo km 2, 28220 Majadahonda, Spain
    Trends Parasitol 18:399-405. 2002
    ..Such studies are essential to determine the basis of the canine protective immune response and to establish a laboratory model, a significant aspect for the development of vaccines against canine leishmaniasis...
  31. pmc Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection
    Yasushi Miyahira
    Atopy Research Center, Department of Parasitology, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Infect Immun 73:7356-65. 2005
    ..cruzi. These results indicated, for the first time, that the induction of immune responses against a single CD8+-T-cell epitope derived from an intrinsic T. cruzi antigen was sufficient to control lethal T. cruzi infection...
  32. pmc Current status of veterinary vaccines
    Els N T Meeusen
    Animal Biotechnology Research Laboratories, Department of Physiology, Building 13F, Monash University, Clayton, Victoria 3800, Australia
    Clin Microbiol Rev 20:489-510, table of contents. 2007
    ..The continued interaction between animals and human researchers and health professionals will be of major importance for adapting new technologies, providing animal models of disease, and confronting new and emerging infectious diseases...
  33. pmc Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection
    Silvia B Boscardin
    Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de Sao Paulo Escola Paulista de Medicina, Sao Paulo, Sao Paulo, Brazil 04023 062
    Infect Immun 71:2744-57. 2003
    ..We concluded that amastigote cDNA is an interesting source of antigens that can be used for immunological studies, as well as for vaccine development...
  34. ncbi Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals
    L Gradoni
    Dipartimento di Malattie Infettive, Parassitarie e Immunomediate, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Roma, Italy
    Vaccine 23:5245-51. 2005
    ..We conclude that vaccination with MML is not effective to prevent leishmaniasis infection and disease progression in dogs under field conditions...
  35. pmc Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs
    José E Aparicio-Burgos
    Centro de Investigacion y Estudios Avanzados, Universidad Autónoma de Estado de México, Toluca, Mexico
    PLoS Negl Trop Dis 5:e1050. 2011
    ..Trypanosoma cruzi, the etiologic agent of Chagas Disease, is a major vector borne health problem in Latin America and an emerging infectious disease in the United States...
  36. pmc Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
    K J Stacey
    Cambridge Institute for Medical Research, Addenbrooke s Hospital, Cambridge CB2 2XY, United Kingdom
    Infect Immun 67:3719-26. 1999
    ..Our results suggest that with an appropriate antigen, CpG ODN would provide a stable, cost-effective adjuvant for use in vaccination against leishmaniasis...
  37. pmc Theileria parva candidate vaccine antigens recognized by immune bovine cytotoxic T lymphocytes
    Simon P Graham
    International Livestock Research Institute, Nairobi, Kenya
    Proc Natl Acad Sci U S A 103:3286-91. 2006
    ..These data provide a basis for developing a CTL-targeted anti-East Coast fever subunit vaccine. In addition, orthologs of these antigens may be vaccine targets for other apicomplexan parasites...
  38. pmc Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein
    J G Valenzuela
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 4 Center Dr, Rm. 4/126, Bethesda, MD 20892, USA
    J Exp Med 194:331-42. 2001
    ..These results indicate that DTH response against saliva provides most or all of the protective effects of this vaccine and that salivary gland proteins or their cDNAs are viable vaccine targets against leishmaniasis...
  39. ncbi Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response
    Jude E Uzonna
    Department of Pathobiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Immunol 172:3793-7. 2004
    ..Thus, these findings report on attenuated parasites that may be used to induce long-term protection against leishmaniasis and indicate that the immunity induced can be maintained in the absence of a strong Th1 response...
  40. ncbi Trypanosoma cruzi infection from the view of CD8+ T cell immunity--an infection model for developing T cell vaccine
    Yasushi Miyahira
    Department of Global Infectious Diseases and Tropical Medicine, National Defense Medical College, 3 2 Namiki, Tokorozawa City, Saitama 359 8513 Japan
    Parasitol Int 57:38-48. 2008
    ..The current review focuses on the usefulness of T. cruzi infection as a model for developing effective CD8(+) T cell-mediated vaccine against intracellular infectious agents...
  41. ncbi SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection
    Ricardo Silvestre
    Departamento de Bioquímica da Faculdade de Farmácia da Universidade do Porto, Portugal
    J Immunol 179:3161-70. 2007
    ..Furthermore these mutants, which presented attenuated virulence, represent a good model to understand the correlatives of protection in visceral leishmaniasis...
  42. pmc Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene
    H V Nielsen
    Department of Mycobacteria and Parasitology, Statens Serum Institut, University of Copenhagen, Copenhagen, Denmark
    Infect Immun 67:6358-63. 1999
    ..In conclusion, DNA vaccination with p1tPASAG1 gave effective protection in mice against T. gondii infection and the protection could be adoptively transferred by purified CD8(+) T cells...
  43. ncbi Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK
    Maria J Ramiro
    Centro de Investigaciones Biologicas, Velazquez 144, CSIC, Madrid 28006, Spain
    Vaccine 21:2474-84. 2003
    ..This type of DNA/rVV prime/boost immunization approach may have utility against visceral leishmaniasis in dogs...
  44. pmc Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Infect Immun 70:4215-25. 2002
    ....
  45. ncbi Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine
    Gulnara Patricia Borja-Cabrera
    Prof Paulo de Góes, Instituto de Microbiologia, Universidade Federal do Rio de Janeiro UFRJ, CCS, Cidade Universitaria, Ilha do Fundao, Caixa Postal 68040, Rio de Janeiro, CEP 21941 590 RJ, Brazil
    Vaccine 22:2234-43. 2004
    ..All animals showed as well significantly increased percents of CD8 lymphocytes as expected for Quillaja saponin (QuilA) vaccine treatments...
  46. ncbi Differential immune response in mice immunized with the A, R or C domain from TcSP protein of Trypanosoma cruzi or with the coding DNAs
    B Salgado-Jiménez
    Departamento de Infectómica y Patogénesis Molecular, Centro de Investigacion y de Estudios Avanzados del IPN, Mexico, D F, Mexico
    Parasite Immunol 35:32-41. 2013
    ..DNA-based immunization with DNA coding for the repeats domain of TcSP is a good candidate for the development of a vaccine against experimental T. cruzi infection...
  47. ncbi Immune responses during pregnancy in heifers naturally infected with Neospora caninum with and without immunization
    Aurélie G Andrianarivo
    Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, 1 Shields Avenue, Davis, CA 95616, USA
    Parasitol Res 96:24-31. 2005
    ..These results indicate that reactivation of a latent infection occurred in the naturally infected heifers, regardless of their immunization status, and was associated with increased parasite-specific antibodies, mainly IgG(2)...
  48. ncbi Toxoplasma gondii: immunogenicity and protection by P30 peptides in a murine model
    Heber Siachoque
    Laboratorio de Inmunologia, Facultad de Medicina, Universidad del Rosario, Bogota, Colombia
    Exp Parasitol 114:62-5. 2006
    ..Our work shows that vaccination with peptides from the carboxy-terminal positions of SAG1 major surface protein of Toxoplasma protects mice against a lethal challenge...
  49. pmc Vaccines against Toxoplasma gondii: status, challenges and future directions
    Qi Liu
    Department of Parasitology, Shandong University School of Medicine, Jinan, Shandong, China
    Hum Vaccin Immunother 8:1305-8. 2012
    ..Finally suggestions are made on possible directions for future research on the development of vaccines against T. gondii...
  50. pmc DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection
    L Planelles
    , , CSIC, 18001 Granada, Spain
    Infect Immun 69:6558-63. 2001
    ..Moreover, protection against the parasite challenge was observed after immunization with the chimeric gene...
  51. ncbi Leishmaniasis: current status of vaccine development
    Bindu Sukumaran
    School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India
    Curr Mol Med 4:667-79. 2004
    ..Thus, DNA immunization may offer an attractive alternative strategy against leishmaniasis. We present here the current status of vaccine development against leishmaniasis...
  52. ncbi Vaccination of chickens with DNA vaccine expressing Eimeria tenella MZ5-7 against coccidiosis
    - Geriletu
    College of Veterinary Medicine, Nanjing Agricultural University, 1 Weigang, Nanjing 210095, China
    Vet Parasitol 177:6-12. 2011
    ..0-MZ group and all the three control groups. In short, MZ5-7 was an effective candidate antigen for vaccine and co-expression of cytokine with antigen was an alternative method to enhance the immunity DNA vaccine...
  53. ncbi Eimeria maxima recombinant Gam82 gametocyte antigen vaccine protects against coccidiosis and augments humoral and cell-mediated immunity
    Seung I Jang
    Animal Parasitic Diseases Laboratory, Animal and Natural Resources Institute, Agricultural Research Service, U S Department of Agriculture, Beltsville, MD 20705, USA
    Vaccine 28:2980-5. 2010
    ..These results demonstrate that the Gam82 recombinant protein protects against E. maxima and augments humoral and cell-mediated immunity...
  54. ncbi Protective effect of a naked DNA vaccine cocktail against lethal toxoplasmosis in mice
    Alberto Fachado
    Laboratory of Autoimmunity and Immunoregulation, Department of Immunology, Oswaldo Cruz Institute, Fiocruz Av Brasil, 4365, Rio de Janeiro 21045 900, Brazil
    Vaccine 21:1327-35. 2003
    ..These results support further investigations to achieve a multigene anti-T. gondii DNA vaccine...
  55. ncbi Intraperitoneal and intra-nasal vaccination of mice with three distinct recombinant Neospora caninum antigens results in differential effects with regard to protection against experimental challenge with Neospora caninum tachyzoites
    K Debache
    Institute of Parasitology, Vetsuisse Faculty, University of Berne, Langgass strasse 122, CH 3012 Berne, Switzerland
    Parasitology 137:229-40. 2010
    ..In the case of recNcPDI, the intra-nasal route provides a platform to generate a highly protective immune response...
  56. ncbi Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2
    Xuefeng Duan
    Department of Parasitology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Vaccine 27:6154-9. 2009
    ..cruzi are interesting candidates for the development of a new mode of recombinant viral vaccine against Chagas' disease...
  57. pmc C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice
    Delaram Doroud
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    PLoS Negl Trop Dis 5:e1236. 2011
    ..Therefore, undefined effect of cationic solid lipid nanoparticles (cSLN) as an adjuvant in enhancing the immune response toward leishmanial antigens led us to refocus our vaccine development projects...
  58. ncbi A combination of antigenic regions of Toxoplasma gondii microneme proteins induces protective immunity against oral infection with parasite cysts
    Elisa Beghetto
    Kenton Laboratories, Rome, Italy
    J Infect Dis 191:637-45. 2005
    ....
  59. ncbi Current status of toxoplasmosis vaccine development
    Jozef Kur
    Gdansk University of Technology, Chemical Faculty, Department of Microbiology, Narutowicza 11 12, 80 952 Gdansk, Poland
    Expert Rev Vaccines 8:791-808. 2009
    ..Recent progress in knowledge of the protective immune response generated by T. gondii and the current status of development of a vaccine for toxoplasmosis are highlighted...
  60. ncbi Montanide™ ISA 71 VG adjuvant enhances antibody and cell-mediated immune responses to profilin subunit antigen vaccination and promotes protection against Eimeria acervulina and Eimeria tenella
    Seung I Jang
    Animal Parasitic Diseases Laboratory, Animal and Natural Resources Institute, Agricultural Research Service, United States Department of Agriculture, Beltsville, MD 20705, USA
    Exp Parasitol 127:178-83. 2011
    ..These results demonstrate that the recombinant profilin subunit vaccine, when given in combination with Montanide™ ISA 71 VG, augments protective immunity against E. acervulina and E. tenella...
  61. pmc Evaluation of protective immune responses induced by DNA vaccines encoding Toxoplasma gondii surface antigen 1 (SAG1) and 14-3-3 protein in BALB/c mice
    Min Meng
    Department of Parasitology, Shandong University School of Medicine, Jinan, Shandong Province, Peoples Republic of China
    Parasit Vectors 5:273. 2012
    ..In this study, we evaluated the immune responses induced by recombinant plasmids encoding T. gondii surface antigen 1 (SAG1) and 14-3-3 protein by immunizing BALB/c mice intramuscularly...
  62. ncbi Efficacy of DNA vaccines carrying Eimeria acervulina lactate dehydrogenase antigen gene against coccidiosis
    Hongyan Song
    College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, Jiangsu 210095, PR China
    Exp Parasitol 126:224-31. 2010
    ..The results provided the first proof that DNA vaccine carrying E. acervulina LDH antigen gene induced protective immunity against homologous infection and its effect could be enhanced by co-expression of chicken IL-2 or IFN-gamma...
  63. pmc Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection
    Eiji Takayama
    Department of Global Infectious Diseases and Tropical Medicine, National Defense Medical College, Tokorozawa City, Saitama, Japan
    Int J Parasitol 40:1549-61. 2010
    ....
  64. ncbi Embryo vaccination against Eimeria tenella and E. acervulina infections using recombinant proteins and cytokine adjuvants
    Hyun S Lillehoj
    Animal Parasitic Diseases Laboratory, Animal and Natural Resources Institute, Agricultural Research Service, United States Department of Agriculture, Beltsville, Maryland 20705, USA
    J Parasitol 91:666-73. 2005
    ..acervulina. Taken together, these results indicate that in ovo vaccination with the EtMIC2 protein plus cytokine/chemokine genes may be an effective method to control coccidiosis...
  65. ncbi Protective immune response against Toxoplasma gondii elicited by a recombinant DNA vaccine with a novel genetic adjuvant
    Huaiyu Zhou
    Department of Parasitology, Shandong University School of Medicine, Jinan, Shandong, PR China
    Vaccine 30:1800-6. 2012
    ..In addition, the adjuvant pSPreS2 formulated with DNA vaccine induced a Th1 type of immune response and therefore might be a novel genetic adjuvant to DNA vaccine for further investigation...
  66. ncbi Identification of Eimeria tenella genes encoding for secretory proteins and evaluation of candidates by DNA immunisation studies in chickens
    Christian Klotz
    Department of Molecular Parasitology, Humboldt University Berlin, Philippstrasse 13, 10115 Berlin, Germany
    Vaccine 25:6625-34. 2007
    ..Our approach represents a rapid screening to identify and test putative new vaccine candidates from E. tenella sporozoites that could also be adopted to other apicomplexan parasites...
  67. ncbi Intranasal immunisation with Toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cell-mediated immunity in sheep
    A C Stanley
    Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, UK
    Vaccine 22:3929-41. 2004
    ..These studies show that intra-nasal delivery has the potential to be an effective route for mucosal immunisation in sheep...
  68. ncbi Toxoplasma gondii: DNA vaccination with genes encoding antigens MIC2, M2AP, AMA1 and BAG1 and evaluation of their immunogenic potential
    George Dautu
    National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido, Japan
    Exp Parasitol 116:273-82. 2007
    ..Therefore, the AMA1 gene appears to generate a strong specific immune response and also provides effective protection against toxoplasmosis more than the MIC2, M2AP and BAG1 genes...
  69. pmc Biological role of surface Toxoplasma gondii antigen in development of vaccine
    Ke Yi Liu
    Shandong Institute of Parasitic Diseases, Jining Taibai Zhong Road 11, Jining 272033, Shandong Province, China
    World J Gastroenterol 12:2363-8. 2006
    ..To analyze the biological role of the surface antigen of Toxoplasma gondii (T gondii) in development of vaccine...
  70. ncbi Evaluation of immune responses in sheep induced by DNA immunization with genes encoding GRA1, GRA4, GRA6 and GRA7 antigens of Toxoplasma gondii
    Elzbieta Hiszczynska-Sawicka
    Faculty of Agriculture and Life Sciences, Lincoln University, PO Box 84, Lincoln, Canterbury, New Zealand
    Vet Parasitol 177:281-9. 2011
    ..The results demonstrate that the intramuscular injection of sheep with a DNA liposome formulated plasmid coding for GRA proteins is an effective system that induces a significant immune response against T. gondii...
  71. pmc Field application of a subunit vaccine against an enteric protozoan disease
    Michael G Wallach
    Institute for the Biotechnology of Infectious Diseases, University of Technology Sydney, Broadway, Australia
    PLoS ONE 3:e3948. 2008
    ..Coccidiosis is a major global veterinary health problem in intensively reared chickens. It is caused by apicomplexan parasites of the genus Eimeria...
  72. ncbi Vaccination of chickens with DNA vaccine encoding Eimeria acervulina 3-1E and chicken IL-15 offers protection against homologous challenge
    Dexing Ma
    College of Veterinary Medicine, Northeast Agricultural University, Harbin, Heilongjiang, China
    Exp Parasitol 127:208-14. 2011
    ....
  73. pmc DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice
    Uta G Lange
    Cambridge Institute for Medical Research, and Department of Medicine, School of Clinical Medicine, University of Cambridge, United Kingdom
    Infect Immun 72:4924-8. 2004
    ....
  74. pmc Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease
    Eduardo L V Silveira
    Centro Interdisciplinar de Terapia Gênica, Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de Sao Paulo Escola Paulista de Medicina, Rua Mirassol, 207, Sao Paulo, Brazil
    Clin Vaccine Immunol 15:1292-300. 2008
    ..In conclusion, our approach allowed us to successfully identify two novel protective ORFs which we consider interesting for future studies on the immune response to Chagas' disease...
  75. ncbi Protective immunity against trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase
    José Ronnie Vasconcelos
    Centro Interdisciplinar de Terapia Gênica CINTERGEN, Universidade Federal de Sao Paulo Escola Paulista de Medicina, Sao Paulo, SP, Brazil, 04044 010
    Hum Gene Ther 15:878-86. 2004
    ..Our results reinforce the prophylactic potential of genetic vaccination with asp-2 and ts genes by describing protective immunity against lethal T. cruzi infection and chronic tissue pathology in a highly susceptible mouse strain...
  76. ncbi Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice
    Sima Rafati
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Exp Parasitol 118:393-401. 2008
    ..This study demonstrated that immunization with CTE display both type 1 and 2 immune signatures in experimental murine model of L. infantum infection...
  77. pmc Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection
    Nisha Garg
    Center for Tropical and Emerging Infectious Diseases and Department of Cellular Biology, University of Georgia, Athens, Georgia 30602, USA
    Infect Immun 70:5547-55. 2002
    ..cruzi infection. In addition, this work provides the first evidence that prophylactic genetic immunization can prevent the development of Chagas' disease...
  78. ncbi Veterinary vaccines against Toxoplasma gondii
    Elisabeth A Innes
    Moredun Research Institute, Pentlands Science Park, Edinburgh
    Mem Inst Oswaldo Cruz 104:246-51. 2009
    ..In this paper we will discuss some of the history, challenges and progress in the development of veterinary vaccines against T. gondii...
  79. ncbi Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis
    Ali Khamesipour
    Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, P O Box 14155 6383, Tehran 14166, Iran
    Vaccine 23:3642-8. 2005
    ..LZ used as live challenge to test vaccine candidates reduces the required sample size, is cost effective for surrogate markers studies and will induce protection in the participants who are not protected by candidate vaccines...
  80. ncbi Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents
    C W Angus
    Office of Review, NCRR NIH, Bethesda, MD 20892, USA gov
    J Infect Dis 181:317-24. 2000
    ..No protection was observed when mice were challenged with the highly virulent RH strain tachyzoites. These results suggest that nucleic acid vaccination can provide protection against T. gondii infection in mice...
  81. pmc Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice
    Shivali Gupta
    Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America
    PLoS Negl Trop Dis 4:e797. 2010
    ..Previously, we have screened the Trypanosoma cruzi sequence database by a computational/bioinformatics approach, and identified antigens that exhibited the characteristics of vaccine candidates...
  82. ncbi Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs
    F S Nogueira
    Faculdade de Medicina Veterinaria e Zootecnia, Universidade Estadual Paulista Julio de Mesquita Filho, UNESP Botucatu Distrito Rubião Jr s n Botucatu SP CEP 18600 000, Brazil
    Vaccine 23:4805-10. 2005
    ..006) being strong markers of infectiousness. The absence of symptoms and of evidence of Leishmania DNA and parasites in Leishmune-vaccinated animals indicates the non-infectious condition of the Leishmune-vaccinated dogs...
  83. pmc The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis
    Alaa Bassuny Ismael
    UMR Université INRA d Immunologie Parasitaire et Vaccinologie, UFR des Sciences Pharmaceutiques, IFR Imagerie et Exploration Fonctionnelles, 37200 Tours, France
    Infect Immun 71:6222-8. 2003
    ..gondii infection. In the attempt to achieve complete protection against toxoplasmosis, MIC3 is a good candidate vaccine which could be combined with other relevant and previously described candidates, such as SAG1 and GRA4...
  84. ncbi Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming
    Daniel F Hoft
    Department of Internal Medicine, Saint Louis University Health Sciences Center, Saint Louis, MO 63110, USA
    J Immunol 179:6889-900. 2007
    ....
  85. ncbi Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis
    Salvador Iborra
    Centro de Biologia Molecular Severo Ochoa, Universidad Autonoma de Madrid, Campus de Cantoblanco, Madrid E 28049, Spain
    Vaccine 22:3865-76. 2004
    ..major infection, and that both CD4(+) and CD8(+) T cells contribute to the resistance of vaccinated mice to cutaneous leishmaniasis...
  86. ncbi Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen
    Slavica Masina
    Institute of Biochemistry, University of Lausanne, Lausanne, Switzerland
    J Infect Dis 188:1250-7. 2003
    ..Our study therefore illustrates the potential use of histone H1 as a vaccine candidate against cutaneous leishmaniasis in humans...
  87. ncbi A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major
    S Rafati
    Department of Immunology, Pasteur Institute of Iran, PO Box 11365 6699, Tehran, Iran
    Vaccine 19:3369-75. 2001
    ..This is the first report demonstrating that co-injection of two genes expressing different antigens induces a long lasting protective response, whereas the separate injection of cysteine proteases genes is not protective...
  88. ncbi Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis
    Azita Zadeh-Vakili
    Department of Immunology, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
    Vaccine 22:1930-40. 2004
    ....
  89. pmc The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge
    L Stobie
    Clinical Immunology Section, Laboratory of Clinical Investigation, Howard Hughes Medical Institute, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 97:8427-32. 2000
    ..Taken together, these data show that IL-12 is essential to sustain a sufficient number of memory/effector Th1 cells generated in vivo to mediate long-term protection to an intracellular pathogen...
  90. ncbi A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice
    Tuhina Mazumdar
    Infectious Diseases Group, Indian Institute of Chemical Biology, 4 Raja S C Mullick Road, Calcutta 700032, India
    Vaccine 22:1162-71. 2004
    ..donovani...
  91. ncbi Poultry coccidiosis: recent advancements in control measures and vaccine development
    Rami A Dalloul
    Animal and Natural Resources Institute, BARC East, Animal Parasitic Diseases Laboratory, USDA ARS, Beltsville, MD 20705, USA
    Expert Rev Vaccines 5:143-63. 2006
    ..This paper aims to review the current progress in understanding the host immune response to Eimeria and discuss current and potential strategies being developed for coccidiosis control in poultry...
  92. pmc Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge
    Matthew H Collins
    Department of Cellular Biology and Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA 30502, USA
    Infect Immun 79:3397-406. 2011
    ..cruzi challenge. These results strongly support the development of whole-organism-based vaccines targeting reservoir species as a means to alleviate the burden of Chagas disease in affected regions...
  93. pmc Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice
    Vandanajay Bhatia
    Department of Microbiology and Immunology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555 1070, USA
    Clin Vaccine Immunol 15:1158-64. 2008
    ..Taken together, these results demonstrate the identification of novel vaccine candidates that provided protection from T. cruzi-induced immunopathology in experimental mice...
  94. pmc Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination
    Bruna C G de Alencar
    Centro Interdisciplinar de Terapia Gênica CINTERGEN, Universidade Federal de Sao Paulo Escola Paulista de Medicina, Rua Mirassol 207, Sao Paulo, SP 04044 010, Brazil
    Infect Immun 77:4383-95. 2009
    ..Our study thus demonstrated a role for perforin and IFN-gamma in a number of T-cell-mediated effector functions and in the antiparasitic immunity generated by a heterologous plasmid DNA prime-adenovirus boost vaccination strategy...
  95. ncbi Immunogenetics of Toxoplasma gondii informs vaccine design
    Fiona L Henriquez
    School of Science, University of the West of Scotland, Paisley, PA1 2BE, UK
    Trends Parasitol 26:550-5. 2010
    ..gondii in conjunction with the development of predictive binding algorithms for MHC I peptides in humans now offers a new opportunity for vaccine development against this medically important pathogen...
  96. ncbi Vaccines against leishmaniasis
    F Modabber
    UNDP World Bank WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland
    Ann Trop Med Parasitol 89:83-8. 1995
    ..In the present article, the advantages and disadvantages of each approach to vaccine development are discussed and the progress being made is briefly reviewed...
  97. pmc Deficient humoral responses underlie susceptibility to Toxoplasma gondii in CD4-deficient mice
    Lawrence L Johnson
    Trudeau Institute, Inc, Saranac Lake, New York 12983, USA
    Infect Immun 70:185-91. 2002
    ..gondii infections and against challenge infections with highly virulent tachyzoites in immunized mice via their role as helper cells for production of isotype-switched antibodies...
  98. ncbi Importance of CD8 T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines
    Mauricio M Rodrigues
    Departamento de Microbiologia, Imunologia e Parasitologia, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, 04023 062 Sao Paulo, SP, Brasil
    An Acad Bras Cienc 75:443-68. 2003
    ..The results obtained using experimental models have led to clinical vaccination trials that are currently underway...
  99. ncbi Prevention of vertical transmission of Neospora caninum in BALB/c mice by recombinant vaccinia virus carrying NcSRS2 gene
    Y Nishikawa
    The National Research Center for Protozoan Diseases, Obihiro University, Nishi 2-11, Inadacho, Obihiro, 080-8555, Hokkaido, Japan
    Vaccine 19:1710-6. 2001
    ..caninum. In conclusion, it is expected that vv/Nc-p43 can be used as an effective live vaccine to prevent vertical transmission of N. caninum in natural hosts...
  100. ncbi A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis
    Poonam Tewary
    School of Life Sciences, Jawaharlal Nehru University, New Delhi, India
    J Infect Dis 191:2130-7. 2005
    ..We describe the effectiveness of a prime-boost vaccination regimen using the open-reading frame (ORFF) gene from the LD1 locus of Leishmania donovani...
  101. pmc Immune responses to gp82 provide protection against mucosal Trypanosoma cruzi infection
    Christopher S Eickhoff
    Departamento de Microbiologia, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brasil
    Mem Inst Oswaldo Cruz 105:687-91. 2010
    ..More importantly, these CpG-gp82-immunized mice were significantly protected from a biologically relevant oral parasite challenge...

Research Grants40

  1. MOLECULAR TOOLS TO DEVELOP HAMSTER MODELS OF DISEASE
    Peter Melby; Fiscal Year: 2003
    ..This work will have particular relevance to research traditionally funded through a number of NIH institutes including the NCI, NIAID, NHLBI, NIA, NIAMS, and NIDR. ..
  2. VACCINATION OF DOGS TO REDUCE TRANSMISSION OF LEISHMANIA
    Peter Melby; Fiscal Year: 2003
    ..Successful vaccination of dogs in an endemic could reduce both enzootic (among the canine reservoir) and zoonotic (from the canine reservoir to humans) transmission. ..
  3. NOS2 and arginase in visceral leishmaniasis
    Peter Melby; Fiscal Year: 2009
    ..These studies in the hamster will fill a knowledge gap by defining mechanisms of disease and immunity that are strikingly different from those of the murine model. ..
  4. EFFECT OF MORPHINE ON IMMUNE RESISTANCE TO T GONDII
    Lawrence Johnson; Fiscal Year: 2002
    ..Together, these studies will provide a comprehensive immunological foundation upon which to build detailed further analyses of the effects of an opioid drug on immunity to opportunistic infection. ..
  5. Regulation of innate immunity to infection
    Lawrence Johnson; Fiscal Year: 2005
    ..Thus, the proposed studies will form a foundation on which to build future studies to examine how regulation of innate immunity impacts acquired immunity to infection and vaccination. ..
  6. Vaccine Induced Mucosal Protection Against TB Infection
    DANIEL HOFT; Fiscal Year: 2005
    ..Prime/boosting strategies found to prevent BCG infection after aerosol challenges will be studied for the ability to prevent infection with virulent M. tuberculosis by aerosol challenge. ..
  7. B CELL DEPENDENT IMMUNITY TO TOXOPLASMA GONDII
    Lawrence Johnson; Fiscal Year: 2004
    ..Also, the role of B cells in protection against congenital T. gondii infection and the influence of Toxoplasma-specific antibodies on the resistance of mice infected as neonates will be analyzed. ..
  8. Vaccine Discovery for Chagas Disease
    Rick Tarleton; Fiscal Year: 2008
    ..Genes cloned in this process will be used to produce and test protective cocktails of genes in the vaccination studies described in Project 3...
  9. ADHERENCE BLOCKING VACCINE FOR AMEBIASIS
    William Petri; Fiscal Year: 2003
    ..In Project 3, the applicants will attempt to develop a novel adjuvant, based on the ricin B subunit to improve the immunogenicity of proteins in plants. ..
  10. Drug Discovery Consortium for Chagas Disease
    Rick L Tarleton; Fiscal Year: 2010
    ..The focus of this proposal is the discovery and development of drugs to treat this infection. ..
  11. TRYPANOSOMA CRUZI MUCOSAL & SYSTEMIC PROTECTIVE IMMUNITY
    DANIEL HOFT; Fiscal Year: 2008
    ..Chemokine and/or integrin receptor expression will be studied by flow cytometry and RT-Real-Time PCR, and the in vivo effects of defective chemokine and integrin binding and/or signaling will be evaluated. [unreadable] [unreadable]..
  12. Rapid Diagnostics for Category B Enteropathogens
    William Petri; Fiscal Year: 2007
    ..Successful completion of these studies will yield high throughput diagnostic tests that target multiple enteropathogens simultaneously in a single sample. ..
  13. CD8+ T cell and Trypanosoma cruzi infection
    Rick Tarleton; Fiscal Year: 2009
    ..cruzi will be determined and the biological significance of the effect of this antagonism of the generation and effector function of CD8+ T cells will be determined. ..
  14. Microarray analysis of gene expresion in T. cruzi
    Rick Tarleton; Fiscal Year: 2006
    ..Completion of this study will provide valuable data on the expression of genes in T. cruzi, especially the many that are "hypothetical," and provide a starting point for elucidating the functions of these genes. ..
  15. GENE EXPRESSION IN ENTAMOEBA HISTOLYTICA
    William Petri; Fiscal Year: 2008
    ..Successful completion of these studies will provide insight into transcription regulation of virulence factors by the novel mechanism of direct calcium control of an EF-hand containing transcription factor. ..
  16. Antigen Detection Assay for Tuberculosis
    Antonio Campos Neto; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  17. Mucosal immune regulation in murine amebic colitis
    Eric Houpt; Fiscal Year: 2007
    ..The comprehensive approach in training and research laid out in this research proposal will guide the applicant towards his goal of being an independent investigator in immunoparasitology. ..
  18. Multiplex bead-PCR diagnosis for AIDS diarrhea
    Eric Houpt; Fiscal Year: 2007
    ..Finally, syndrome-based multiplex diagnosis is the platform of the future for clinical microbiology, and if this assay works on stool it should work on sputum, blood, or spinal fluid. [unreadable] [unreadable] [unreadable]..
  19. Adherence of malaria-infected red cells
    Alan Cowman; Fiscal Year: 2009
    ..These studies will contribute to and increased understanding of the pathophysiology of falciparum malaria. ..
  20. GAMMA/DELTA T CELLS AND PATHOGEN INDUCED IMMUNE RESPONSE
    Phillip Scott; Fiscal Year: 2003
    ..abstract_text> ..
  21. TRYPANASOMA CRUZI GENOME-SBRI
    Kenneth Stuart; Fiscal Year: 2004
    ..This information will aid the development on diagnostic, therapeutic, and preventative measures, as well as further our understanding of fundamental molecular phenomena. ..
  22. Genome Evolution, Innovation and Adaptation in the Apicomplexa
    Jessica C Kissinger; Fiscal Year: 2010
    ..The results of these studies will be shared with the larger research community via publication and deposition in community databases and Bioinformatics Resource Centers. ..
  23. The Role of Babesia bovis MSA-1 in Erythrocyte Invasion
    Tanya LeRoith; Fiscal Year: 2004
    ..The results of this project, as well as the transfection techniques that will be developed, will allow us to begin targeting regions of functional significance in these proteins for further study...
  24. Mouse Strain dependent innate resistance to intestinal amebiasis
    Eric Houpt; Fiscal Year: 2009
    ....
  25. VACCINE DEVELOPMENT IN TUBERCULOSIS
    Antonio Campos Neto; Fiscal Year: 2004
    ..In addition to the evaluation of these antigens, we will characterize and clone other vaccine candidates using recently developed approaches for the direct identification of both CD4 and CD8 T cell antigens. ..
  26. Abnormalities of Mitochondria in Chagasic Myocarditis
    Nisha Garg; Fiscal Year: 2003
    ..The proposed studies will determine the pathophysiological contribution of host mitochondrial abnormalities in the progression of chagas disease. ..
  27. Characterization of a vaccine against Chlamydia trachomatis
    RHEA COLER; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  28. Initiation Of Immune Responses in Chronic Leishmaniasis
    Phillip Scott; Fiscal Year: 2008
    ..Taken together, these experiments should provide the foundation for the development of new immunotherapies for chronic leishmaniasis. ..
  29. Chemokines in pathogenesis of Experimental Arthritis
    SEEMA SINGH AHUJA; Fiscal Year: 2010
    ..Thus information obtained from proposed studies which explore how CCR2 modulates arthritis will have significant impact on potential therapeutic strategies to treat this chronic deblitating disease. ..
  30. Targeted DNA extraction for Tuberculosis PCR from sputum
    Eric Houpt; Fiscal Year: 2007
    ..The most sensitive procedure will be taken in Phase II and adapted to high-throughput DNA extraction platforms and compared against the standard E- MTD assay. [unreadable] [unreadable] [unreadable]..
  31. GLUCOCORTICOID RECEPTOR-MEDIATED CATARACT
    Eric James; Fiscal Year: 2003
    ....
  32. Immune Pathways as Prerequisites for Adjuvants' Efficacy
    George Hui; Fiscal Year: 2004
    ....
  33. B.abortus-based vaccine against viral hemorrhagic fevers
    Ramesh Vemulapalli; Fiscal Year: 2004
    ..abstract_text> ..
  34. Chemokine System in DC and Lymphocyte Function
    SEEMA AHUJA; Fiscal Year: 2005
    ....
  35. Vaccine Development in Leishmaniasis
    Phillip Scott; Fiscal Year: 2006
    ..Overall, these experiments will establish the parameters for using LPG2 KO parasites as a vaccine in non-human primates, and provide basic information of wider importance in developing a leishmanial vaccine. [unreadable] [unreadable]..
  36. Generation of babesial surface protein diversity
    SHAWN BERENS; Fiscal Year: 2006
    ..The sponsors collaborate closely in research and have successfully mentored clinicians, graduate students, and post-doctoral fellows to research independence. ..
  37. Real-time PCR diagnostic kit for Giardia and Cryptosporidium
    Eric Houpt; Fiscal Year: 2006
    ..A Phase II application is anticipated to validate the final diagnostic test product against immunoassay for an FDA 501 (k) medical device application. [unreadable] [unreadable] [unreadable]..
  38. Gammacell-40 Exactor Research Irradiator
    Phillip Scott; Fiscal Year: 2007
    ..Each of these will advance our understanding of human diseases. [unreadable] [unreadable] [unreadable]..
  39. Non-replicative Vaccine for Human Brucellosis
    Ramesh Vemulapalli; Fiscal Year: 2011
    ..At present there is no vaccine available for prevention of brucellosis in humans. Research proposed in this application focuses on developing a highly effective and safe Brucella vaccine for human use. ..